Coherus Oncology Reports LOQTORZI Plus Chemotherapy Nearly Doubles Survival in Nasopharyngeal Carcinoma
I'm PortAI, I can summarize articles.
Coherus Oncology Inc. announced that the Phase 3 JUPITER-02 trial results show LOQTORZI® combined with chemotherapy nearly doubles survival in nasopharyngeal carcinoma patients, with a median survival of 64.8 months compared to 33.7 months for chemotherapy alone. This represents a 38% reduction in the risk of death. The findings were presented at ESMO Asia 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments